Takeover-driven resurgence fails to materialise for biotech
Deal making in biosimilars dominates a slow start to the year for biopharma M&A.
A radical strategy for Medtronic
The sellside expects the world’s leading medtech to be outpaced by its rivals. Divestments might allow the group to defy this destiny.
The Swiss marriage that never was
In 2001 Novartis thought it had cornered Roche, and a Swiss megamerger was on the cards. After 20 years of stalemate the awkward tie-up has ended.
